ISRG

healthcare

INTUITIVE SURGICAL INC

medical devicesLarge Cap ($10-200B)1 filings tracked

Signal Timeline

bullishApr 22

Revenue and operating income grew significantly above prior year levels.

earnings beat

90%

bearishApr 22

Service gross margins declined compared to the previous year.

margin compression

60%

bullishApr 22

Company aggressively repurchased over $1.1 billion in common stock.

buyback

70%

bullishApr 22

Acquisition of European distribution assets to move to direct sales.

acquisition

50%

Filing History

10-QApr 22, 2026

Intuitive Surgical's latest quarterly filing presents a classic tension between rapid technological scaling and the operational costs of a maturing platform. On one hand, the company is successfully executing a massive product rollout, with the da Vinci 5 and Ion systems driving significant procedure growth and top-line acceleration. The transition to a direct-sales model in Europe via recent acquisitions further signals a strategic move to capture higher margins globally. On the other hand, the company is navigating a complex macroeconomic landscape characterized by tariff pressures and shifting hospital budgets. The contraction in service margins and the heavy cash commitment to share buybacks suggest that the company is prioritizing shareholder returns and platform dominance at the expense of immediate liquidity. Investors must weigh the strength of the expanding surgical moat against the volatility of usage-based revenue and the rising costs of global operations.